Trial intelligence / Profile preview

V114 vs Prevnar 13 in Healthy Infants

NCT01215188Phase 2Completed

Sponsor
Merck & Co.
Start
Oct 2010
Primary completion
Jul 2012
Modality
Split/Subunit Vaccines
01

Overview

A Phase 2 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Oct 2010; status: completed.

02

Drugs

pneumococcal 15-valent conjugate vaccine
03

Conditions

pneumococcal infection

Beyond the preview

Go deeper on NCT01215188.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01215188.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call